Cluster Randomized Adaptive Experiment — Adaptive Group-Level Randomization
Cluster Randomized Adaptive Experiment · Also known as: adaptive cluster RCT, adaptive group-randomized trial, cluster adaptive design, adaptive cluster trial
A cluster randomized adaptive experiment combines two methodological principles: (1) intact groups such as schools, clinics, or villages are randomly assigned to treatment conditions rather than individuals, and (2) pre-specified rules allow the design to be modified during the trial based on accumulating cluster-level data. Adaptations may include dropping underperforming arms, reallocating clusters, or adjusting sample size, while maintaining statistical validity and controlling Type I error.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use a cluster randomized adaptive experiment when: the intervention must be delivered to intact groups (minimising contamination risk); there are two or more arms and genuine clinical or policy uncertainty about which will prove superior; interim modifications could improve efficiency or participant welfare without compromising validity; and the regulatory or ethical context permits adaptive changes. The design requires a sufficient number of clusters per arm (at minimum 6, ideally 20+ per arm) for the interim estimates of ICC and treatment effect to be meaningful. Do NOT use this design when the number of available clusters is small (fewer than 10 total) — interim estimates will be too unstable to support reliable adaptation decisions; a standard cluster RCT or individually randomized adaptive design will be more appropriate. Avoid it also when resources or timeline do not allow the operational complexity of independent data monitoring infrastructure and simulation-based protocol planning.
Strengths & limitations
- Combines contamination control from cluster-level randomization with the efficiency gains of adaptive modification, making it particularly valuable in community and public-health trials.
- Pre-specified arm-dropping rules allow resources to be reallocated away from ineffective interventions, reducing exposure of clusters to inferior treatments.
- Sample-size re-estimation on the basis of observed ICC protects against under-powered trials when the assumed ICC was incorrect at the design stage.
- The structured interim review process via an IDMC improves governance and participant safety monitoring throughout the trial.
- Can meaningfully reduce total sample size compared to a fixed cluster RCT when early stopping for efficacy or futility is triggered.
- Operationally complex: requires an independent data monitoring committee, pre-specified adaptation rules, simulation-based power analyses, and in regulated settings a formal protocol amendment process for each adaptation type.
- Interim analyses with small numbers of clusters produce highly variable estimates of the ICC and treatment effect, making adaptation decisions unreliable — a minimum number of clusters must be observed before any interim look.
- Cluster dropout (an entire cluster withdrawing) between randomization and the interim look can destabilise the adaptation decision rules in ways that are difficult to correct analytically.
- Regulatory acceptance varies: while adaptive RCTs are well-accepted in drug trials, cluster adaptive designs in public health and education settings have less standardised guidance, requiring more detailed justification in ethics and funding applications.
- Type I error control across both the clustering structure and the sequential testing boundary requires specialised software and statistical expertise beyond that needed for a standard cluster RCT.
Frequently asked
How is this different from a standard cluster RCT?
A standard cluster RCT has a fixed design — the number of clusters, arms, and analytic plan are set before the trial begins and do not change. A cluster randomized adaptive experiment adds pre-specified rules that permit modifications (arm dropping, sample-size re-estimation, early stopping) based on interim data, while controlling the overall Type I error rate. The cluster-level randomization in both designs serves the same purpose — preventing contamination — but the adaptive design can be more efficient when there is genuine uncertainty about which arm will prove superior.
Do I need a data monitoring committee?
Yes. Any trial that conducts interim analyses with the possibility of modifying the design requires an independent data monitoring committee (IDMC) to review the unblinded data. The IDMC applies the pre-specified decision rules and makes recommendations to the trial steering committee. Without an IDMC, there is no credible mechanism for preventing post-hoc manipulation of the adaptation rules, which would invalidate the Type I error guarantee.
How many clusters do I need before the first interim look?
There is no single universal rule, but a practical guideline is that at least 6 clusters per arm should have completed follow-up before any interim adaptation decision is made, and 10–15 per arm is preferable for reliable ICC estimation. With very few clusters, the confidence interval around the interim effect estimate is so wide that adaptation decisions carry a high risk of being wrong — dropping a genuinely effective arm (false futility) or continuing a genuinely ineffective one.
Can I use this design for non-clinical settings like education or development economics?
Yes, and this is one of the most promising areas for cluster adaptive designs. Educational trials often randomize at the school or classroom level; development economics trials randomize villages or districts. In these settings regulatory approval is not required, but pre-registration (e.g., on the AEA registry or OSF) and a detailed pre-specified analysis plan serve the same function as a regulatory-compliant protocol — they lock in the adaptation rules before data are examined and provide a public accountability mechanism.
What software can I use for planning and analysis?
For simulation-based planning: the R packages clusterPower, CRTpowerPack (cluster sample size), and rpact or gsDesign (adaptive boundaries) can be combined; EAST (Cytel) handles both cluster and adaptive elements in a commercial package. For analysis: lme4 or nlme in R for mixed-effects models accounting for clustering, combined with gsDesign or rpact for sequential p-value adjustment. No single package handles all aspects seamlessly — consultation with a biostatistician experienced in both cluster designs and adaptive methods is strongly recommended.
Sources
- Hayes, R. J., & Moulton, L. H. (2017). Cluster Randomised Trials (2nd ed.). CRC Press / Chapman & Hall. ISBN: 978-1498728225
- Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., ... & Jaki, T. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 16(1), 29. DOI: 10.1186/s12916-018-1017-7 ↗
How to cite this page
ScholarGate. (2026, June 3). Cluster Randomized Adaptive Experiment. ScholarGate. https://scholargate.app/en/experimental-design/cluster-randomized-adaptive-experiment
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive ExperimentExperimental design↔ compare
- Adaptive Randomized Controlled TrialExperimental design↔ compare
- Blocked Randomized Controlled TrialExperimental design↔ compare
- Cluster Randomized Controlled TrialExperimental design↔ compare
- Multi-arm experimentExperimental design↔ compare